TY - JOUR
A1 - Hassan, Abdulaziz
A1 - Dogara, Livingstone
A1 - Babadoko, Ahmadu
A1 - Awwalu, Sani
A1 - Mamman, Aisha
T1 - Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
Y1 - 2015/1/1
JF - Nigerian Medical Journal
JO - Niger Med J
SP - 74
EP - 76
VL - 56
IS - 1
UR - https://www.nigeriamedj.com/article.asp?issn=0300-1652;year=2015;volume=56;issue=1;spage=74;epage=76;aulast=Hassan
DO - 10.4103/0300-1652.149177
N2 - The World Health Organisation (WHO) classifies myeloproliferative neoplasm (MPN) into BCR-ABL positive chronic myeloid leukaemia (CML Ph + ) and Ph− MPN. The JAK2 V617F mutation is specific for Ph− MPN and occurs in approximately 50% of primary myelofibrosis. Earlier reports suggest that the occurrence of JAK2 and BCR-ABL mutations are mutually exclusive. However, recent reports have documented the coexistence of BCR-ABL and JAK2 mutation in the same patient mostly following treatment with tyrosine kinase inhibitors (TKIs). We thus report a 60-year-old male with atypical clinical and laboratory features of MPN and the presence of both BCR-ABL and JAK2 Mutations.
ER -